Volume 89 Issue 31 | pp. 23-25
Issue Date: August 1, 2011

Behind The Surge

A swell in FDA approvals has many wondering whether the drug industry has finally gotten better at R&D
Department: Business
Keywords: FDA, new drug approvals, cancer

Since January, the Food & Drug Administration has approved as many new molecular entities, or NMEs, as it did in all of 2010. The statistic has led drug industry watchers to wonder what prompted the seemingly sudden improvement in productivity and to ask whether companies can sustain this pace of new approvals.

A popular explanation for the surge in new drug approvals, or NDAs, is that big drug companies, after a period of R&D . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society